Celecoxib, rofecoxib, and acute temporary visual impairment

摘要

We present evidence of acute severe temporary visual disturbance with two of the new selective anti-inflammatory cyclo-oxygenase-2 (COX 2) inhibitors. We report two cases, one of temporary blindness and one that suggests a visual field defect together with five other less specific reports of blurred or abnormal vision (table 1). These reports were received while monitoring celecoxib and rofecoxib in the New Zealand intensive medicines monitoring programme. This national programme monitors selected newly introduced drugs. Monitoring of the COX 2 inhibitors, celecoxib and rofecoxib started in December 2000.